Advances in immunosuppressive drug therapy for use in autoimmune disease and systemic vasculitis

Seminars in Respiratory and Critical Care Medicine

Volumn 25, Issue 5, 2004, Pages 581-594

  Marder, Wendy ^b   McCune, W Joseph ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Azathioprine; Cyclophosphamide; Cyclosporine; Immunosuppression; Leflunomide; Methotrexate; Mycophenolate mofetil; Pulmonary

Indexed keywords

ACROLEIN; AMINOPTERIN; AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIHYDROFOLATE REDUCTASE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ALOPECIA; AUTOIMMUNE DISEASE; BLADDER CARCINOMA; BLOOD TOXICITY; DIARRHEA; DRUG EFFECT; DRUG MECHANISM; GASTROINTESTINAL TOXICITY; GENETIC PREDISPOSITION; GONAD FUNCTION; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTIOUS COMPLICATION; LIVER TOXICITY; LUNG TOXICITY; MAINTENANCE THERAPY; NAUSEA; PRIORITY JOURNAL; REMISSION; REVIEW; SIDE EFFECT; SYSTEMIC VASCULITIS; TERATOGENICITY; WEGENER GRANULOMATOSIS;

EID: 8744239492     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-836149     Document Type: Review

References (132)

1. Turk JL, Poulter LW. Selective depletion of lymphoid tissue by cyclophosphamide. Clin Exp Immunol 1972;10:285-296
2. Clements PJ, Yu DT, Levy J, et al. Effects of cyclophosphamide on B- and T-lymphocytes in rheumatoid arthritis. Arthritis Rheum 1974;17:347-353
3. Hurd ER, Giuliano VJ. The effect of cyclophosphamide on B and T lymphocytes in patients with connective tissue diseases. Arthritis Rheum 1975;18:67-75
4. McCune WJ, Golbus J, Zeldes W, et al. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988;318:1423-1431
5. Chiorazzi N, Fox DA, Katz DH. Hapten-specific IgE antibody responses in mice, VI: Selective enhancement of IgE antibody production by low doses of X-irradiation and by cyclophosphamide. J Immunol 1976;117(5 pt 1):1629-1637
6. Malik SW, Myers JL, DeRemee RA, et al. Lung toxicity associated with cyclophosphamide use: two distinct patterns. Am J Respir Crit Care Med 1996;154(6 pt 1):1851-1856
7. Mark GJ, Lehimgar-Zadeh A, Ragsdale BD. Cyclophosphamide pneumonitis. Thorax 1978;33:89-93
8. Lynch JP III, Chavis AD. Chronic Interstitial Pulmonary Disorders. Boston: Little, Brown; 1992
9. Myers JL. Diagnosis of drug reactions in the lung. Monogr Pathol 1993;36:32-53
10. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-498
11. Baker GL, Kahl LE, Zee BC, et al. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: long-term case-control follow-up study. Am J Med 1987;83:1-9
12. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996;124:477-484
13. Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995;87:524-530
14. Fox DA, McCune WJ. Immunologic and clinical effects of cytotoxic drugs used in the treatment of rheumatoid arthritis and systemic lupus erythematosus. Concepts Immunopathol 1989;7:20-78
15. Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a 20-year followup study. Arthritis Rheum 1995;38:1120-1127
16. Ognenovski V, Marder W, Somers E, et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004;31:1763-1767
17. Lynch JP III, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997;155:395-420
18. Koyama H, Wada T, Nishizawa Y, et al. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977;39:1403-1409
19. Boumpas DT, Chrousos GP, Wilder RL, et al. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993;119:1198-1208
20. Blumenfeld Z. Ovarian rescue/protection from chemotherapeutic agents. J Soc Gynecol Investig 2001;8(suppl 1):S60-S64
21. Blumenfeld Z, Shapiro D, Shteinberg M, et al. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000;9:401-405
22. Pereyra Pacheco B, Mendez Ribas JM, Milone G, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 2001;81:391-397
23. McCune WJ, Somers E, Christman G, et al. Use of leuprolide acetate for ovarian protection during cyclophosphamide therapy of women with severe lupus. Arthritis Rheum 2002;44:S2006
24. Hoorweg-Nijman JJ, Delemarre-van de Waal HA, de Waal FC, et al. Cyclophosphamide-induced disturbance of gonadotropin secretion manifesting testicular damage. Acta Endocrinol (Copenh) 1992;126:143-148
25. Masala A, Faedda R, Alagna S, et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med 1997;126:292-295
26. Huynh-Do U, Gantenbein H, Binswanger U. Pneumocystis carinii pneumonia during immunosuppressive therapy for antineutrophil cytoplasmic autoantibody-positive vasculitis. Arch Intern Med 1995;155:872-874
27. Bradley JD, Brandt KD, Katz BP. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989;32:45-53
28. de Groot K, Adu D, Savage CO, EUVAS (European vasculitis study group). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001;16:2018-2027
29. Mitrovic D, Popovic M, Stefanovic D, Glisic B, Dimitrijevic M. Immunosuppressive therapy with cyclophosphamide pulse doses in Wegener's granulomatosis. Transplant Proc 2001;33:2378-2379
30. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-980
31. Lehman TJ, Edelheit BS, Onel KB. Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis. Ann Rheum Dis 2004;63:321-323
32. Burt RK, Traynor AE. SLE: hematopoietic stem cell transplantation for systemic lupus erythematosus. Arthritis Res Ther 2003;5:207-209
33. Petri M Jr, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003;48:166-173
34. Langford CA, Talar-Williams C, Barron KS, et al. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003;114:463-469
35. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44
36. Slot MC, Tervaert JW, Boomsma MM, et al. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004;51:269-273
37. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004;51:278-283
38. Metzler C, Fink C, Lamprecht P, et al. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 2004;43:315-320
39. Cannon GW, Jackson CG, Samuelson CO Jr, et al. Chlorambucil therapy in rheumatoid arthritis: clinical experience in 28 patients and literature review. Semin Arthritis Rheum 1985;15:106-118
40. Steinberg AD. Chlorambucil in the treatment of patients with immune-mediated rheumatic diseases. Arthritis Rheum 1993;36:325-328
41. Hemady R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol 1991;35:369-385
42. Reichert LJ, Huysmans FT, Assmann K, et al. Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. Ann Intern Med 1994;121:328-333
43. Sinoway PA, Callen JP. Chlorambucil: an effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum 1993;36:319-324
44. Clements P, Lachenbruch P, Furst D, et al. The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo. Arthritis Rheum 1993;36:1575-1579
45. Fauci AS, Haynes BF, Katz P, et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98:76-85
46. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-154
47. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989;111:641-649
48. Sterneck M, Wiesner R, Ascher N, et al. Azathioprine hepatotoxicity after liver transplantation. Hepatology 1991;14:806-810
49. Bottomley WW, Ford G, Cunliffe WJ, et al. Aggressive squamous cell carcinomas developing in patients receiving long-term azathioprine. Br J Dermatol 1995;133:460-462
50. Smith JL, Wilkinson AH, Hunsicker LG, et al. Increased frequency of posttransplant lymphomas in patients treated with cyclosporin, azathioprine, and prednisone. Transplant Proc 1989;21(1 pt 3):3199-3200
51. Silman AJ, Petrie J, Hazleman B, et al. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20-year follow-up study. Ann Rheum Dis 1988;47:988-992
52. Nero P, Rahman A, Isenberg DA. Does long-term treatment with azathioprine predispose to malignancy and death in patients with systemic lupus erythematosus? Ann Rheum Dis 2004;63:325-326
53. Taylor L, Hughes RAC, McPehrson K. The risk of cancer from azathoprine as a treatment for multiple sclerosis. Eur J Neurol 2004;11:111-142
54. Fraser AG, Orchard TR, Robinson EM, et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002;16:1225-1232
55. Matalon ST, Ornoy A, Lishner M. Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta). Reprod Toxicol 2004;18:219-230
56. Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology 2002;65:240-261
57. Norgard B, Pedersen L, Jacobsen J, et al. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther 2004;19:679-685
58. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000;160:610-619
59. Dean T, Dewey A, Bara A, et al. Azathioprine as an oral corticosteroid sparing agent for asthma. Cochrane Database Syst Rev 2004:CD003270
60. Esdaile JM, Joseph L, MacKenzie T, et al. The benefit of early treatment with immunosuppressive drugs in lupus nephritis. J Rheumatol 1994;21:2046-2051
61. Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-619
62. Ortiz Z, Shea B, Suarez Almazor M, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000:CD000951
63. Ortiz Z, Shea B, Suarez-Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis: a metaanalysis of randomized controlled trials. J Rheumatol 1998;25:36-43
64. Fox DA, McCune WJ. Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum Dis Clin North Am 1994;20:265-299
65. Weinblatt ME. Methotrexate for chronic diseases in adults. N Engl J Med 1995;332:330-331
66. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266-273
67. Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998;102:322-328
68. Rosengren S, Arfors KE, Proctor KG. Potentiation of leukotriene B4-mediated inflammatory response by the adenosine antagonist, 8-phenyl theophylline. Int J Microcirc Clin Exp 1991;10:345-357
69. Lewis JH, Schiff E. Methotrexate-induced chronic liver injury: guidelines for detection and prevention. The ACG Committee on PDA-related matters. American College of Gastroenterology. Am J Gastroenterol 1988;83:1337-1345
70. Weinblatt ME, Fraser P. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum 1989;32:1592-1596
71. Hilsden RJ, Urbanski SJ, Swain MG. End-stage liver disease developing with the use of methotrexate in heterozygous alpha 1-antitrypsin deficiency. Arthritis Rheum 1995;38:1014-1018
72. Cannon GW, Ward JR, Clegg DO, et al. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthritis Rheum 1983;26:1269-1274
73. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 2000;15:373-381
74. Zisman DA, McCune WJ, Tino G, et al. Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:243-252
75. Cottin V, Tebib J, Massonnet B, et al. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 1996;109:933-938
76. Carroll GJ, Thomas R, Phatouros CC, et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 1994;21:51-54
77. Hargreaves MR, Mowat AG, Benson MK. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax 1992;47:628-633
78. Padley SP, Adler B, Hansell DM, et al. High-resolution computed tomography of drug-induced lung disease. Clin Radiol 1992;46:232-236
79. Arakawa H, Yamasaki M, Kurihara Y, et al. Methotrexate-induced pulmonary injury: serial CT findings. J Thorac Imaging 2003;18:231-236
80. White DA, Rankin JA, Stover DE, et al. Methotrexate pneumonitis: bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis 1989;139:18-21
81. Schnabel A, Richter C, Bauerfeind S, et al. Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Thorax 1997;52:377-379
82. Menke DM, Griesser H, Moder KG, et al. Lymphomas in patients with connective tissue disease: comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate. Am J Clin Pathol 2000;113:212-218
83. Patsner B, Kenigsberg D. Successful treatment of persistent ectopic pregnancy with oral methotrexate therapy. Fertil Steril 1988;50:982-983
84. Hoffman GS, Leavitt RY, Kerr GS, et al. Treatment of glucocorticoid- resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994;37:578-582
85. Langford CA, Talar-Williams C, Barron KS, et al. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999;42:2666-2673
86. Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis: long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000;43:1836-1840
87. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev 2000:CD000391
88. de Groot K, Muhler M, Reinhold-Keller E, et al. Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 1998;25:492-495
89. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vase Diffuse Lung Dis 2000;17:60-66
90. Brazelton TR, Morris RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996;8:710-720
91. Palmer G, Burger D, Mezin F, et al. The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes. Arthritis Res Ther 2004;6:R181-R189
92. Bartlett RR, Brendel S, Zielinski T, et al. Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis. Transplant Proc 1996;28:3074-3078
93. John GT, Manivannan J, J Chandy S, et al. Leflunomide therapy for cytomegalovirus disease in renal allograft recipients. Transplantation 2004;77:1460-1461
94. Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two-year follow-up of a double-blind, placebo-controlled trial versus sulfasalazine. Ann Rheum Dis 2001;60:913-923
95. Siva CES, Shepherd R, Cunningham F, et al. Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients. Arthritis Rheum 2003;49:745-751
96. Cohen SB, Iqbal I. Leflunomide. Int J Clin Pract 2003;57:115-120
97. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159:2542-2550
98. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259-266
99. Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vase Diffuse Lung Dis 2004;21:43-48
100. Sintchak MD, Nimmesgern E. The structure of inosine 5′- monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 2000;47:163-184
101. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118
102. Senda M, DeLustro B, Eugui E, et al. Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation 1995;60:1143-1148
103. Allison AC, Eugui EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol 1993;14:353-380
104. Penny MJ, Boyd RA, Hall BM. Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition. J Am Soc Nephrol 1998;9:2272-2282
105. Lipsky JJ. Mycophenolate mofetil. Lancet 1996;348:1357-1359
106. Ginzler EM, Buyon J, Dooley MA, et al. A multicenter study of mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis (LN). Arthritis Rheum 2003;48:S647
107. Riskalla MM, Somers EC, Fatica RA, et al. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1508-1512
108. Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 2002;35:53-61
109. Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-1738
110. Wiederrecht G, Lam E, Hung S, et al. The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci 1993;696:9-19
111. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992;13:136-142
112. Wera S, Zheng L, Hooghe-Peters EL, et al. Cyclosporin A, rapamycin and FK506 decrease prolactin release from rat pituitary cells in primary culture. Endocr Res 1995;21:623-633
113. Timmerman LA, Clipstone NA, Ho SN, et al. Rapid shuttling of NF-AT in discrimination of Ca2+ signals and immunosuppression nuclear factor of activated T cells is associated with a mast cell interleukin 4 transcription complex. Nature 1996;383:837-840
114. Kim WU, Cho ML, Kim SI, et al. Divergent effect of cyclosporine on Th1/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis. J Rheumatol 2000;27:324-331
115. Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993;45:953-1040
116. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med 1992;326:1654-1660
117. Palestine AG, Austin HA III, Balow JE, et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 1986;314:1293-1298
118. Kopp JB, Klotman PE. Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol 1990;1:162-179
119. Keown P, Niese D. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group. Kidney Int 1998;54:938-944
120. Miura K, Nakatani T, Asai T, et al. Role of hypomagnesemia in chronic Cyclosporine nephropathy. Transplantation 2002;73:340-347
121. Foley RJ, Hamner RW, Weinman EJ. Serum potassium concentrations in Cyclosporine- and azathioprine-treated renal transplant patients. Nephron 1985;40:280-285
122. Burke JF Jr, Pirsch JD, Ramos EL, et al. Long-term efficacy and safety of Cyclosporine in renal-transplant recipients. N Engl J Med 1994;331:358-363
123. Arellano F, Krupp P. Malignancies in rheumatoid arthritis patients treated with cyclosporin A. Br J Rheumatol 1993;32(suppl 1):72-75
124. Feutren G. The optimal use of cyclosporin A in autoimmune diseases. J Autoimmun 1992;5(suppl A):183-195
125. Kitridou RC, Goodwin TM. The fetus in systemic lupus erythematosus. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus. 6th ed. Baltimore, MD: Williams & Wilkins; 1997:1023-1040
126. Sajjadi H, Soheilian M, Ahmadieh H, et al. Low-dose cyclosporin-A therapy in Behçet's disease. J Ocul Pharmacol 1994;10:553-560
127. Lebwohl M, Ellis C, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998;39:464-475
128. Wagner SA, Peter RU, Adam O, et al. Therapeutic efficacy of oral low-dose cyclosporin A in severe psoriatic arthritis. Dermatology 1993;186:62-67
129. Hallegua D, Wallace DJ, Metzger AL, et al. Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 2000;9:241-251
130. Landewe RB, Goei The HS, van Rijthoven AW, et al. A randomized, double-blind, 24-week controlled study of low-dose Cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 1994;37:637-643
131. Mobini N, Padilla T Jr, Ahmed AR. Long-term remission in selected patients with pemphigus vulgaris treated with Cyclosporine. J Am Acad Dermatol 1997;36(2 pt 1):264-266
132. Evans DJ, Cullinan P, Geddes DM. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001:CD002993